Compare
Anaptysbio, Inc vs Puma Biotechnology, Inc. vs Arcus Biosciences, Inc. vs IDEAYA Biosciences, Inc.
| Latest fiscal year | Anaptysbio, Inc ANAB | Puma Biotechnology, Inc. PBYI | Arcus Biosciences, Inc. RCUS | IDEAYA Biosciences, Inc. IDYA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $234.60M | $228.37M | $247.00M | $218.71M |
| Revenue growth (YoY) | +157.0% | -0.9% | -4.3% | n/m |
| Gross margin | n/a | 74.5% (computed) | n/a | n/a |
| Operating margin | 20.4% | 16.3% | -156.3% | -72.8% |
| Net margin | -5.6% | 13.6% | -142.9% | -52.0% |
| Net income | -$13.23M | $31.11M | -$353.00M | -$113.70M |
| EPS (Diluted) | -$0.46 | $0.61 | -$3.29 | -$1.28 |
| Operating cash flow | $19.70M | $41.80M | -$482.00M | -$71.10M |
| Free cash flow | $19.61M | $41.73M | -$484.00M | -$73.47M |
| Cash & equivalents | $238.20M | $29.64M | $222.00M | $112.83M |
| Total assets | $364.39M | $216.30M | $1.14B | $1.11B |
| Total liabilities | n/a | $85.96M | n/a | $86.39M |
| Shareholders' equity | $37.21M | $130.34M | $631.00M | $1.02B |
| Return on year-end equity | -35.6% | 23.9% | -55.9% | -11.1% |
| Shares outstanding | 28.02M | 50.41M | 125.30M | 87.80M |
Revenue, most recent five fiscal years
| Fiscal year | Anaptysbio, Inc | Puma Biotechnology, Inc. | Arcus Biosciences, Inc. | IDEAYA Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $234.60M Ended 2025-12-31 | $228.37M Ended 2025-12-31 | $247.00M Ended 2025-12-31 | $218.71M Ended 2025-12-31 |
| 1 year earlier | $91.28M Ended 2024-12-31 | $230.47M Ended 2024-12-31 | $258.00M Ended 2024-12-31 | $7.00M Ended 2024-12-31 |
| 2 years earlier | $17.16M Ended 2023-12-31 | $235.64M Ended 2023-12-31 | $117.00M Ended 2023-12-31 | $23.39M Ended 2023-12-31 |
| 3 years earlier | $10.29M Ended 2022-12-31 | $228.03M Ended 2022-12-31 | $112.00M Ended 2022-12-31 | $50.93M Ended 2022-12-31 |
| 4 years earlier | $63.17M Ended 2021-12-31 | $253.16M Ended 2021-12-31 | $383.00M Ended 2021-12-31 | $27.94M Ended 2021-12-31 |